Literature DB >> 10780124

Treatment of spit tobacco users with transdermal nicotine system and mint snuff.

D K Hatsukami1, M Grillo, R Boyle, S Allen, J Jensen, R Bliss, S Brown.   

Abstract

The purpose of this study was to examine the effects of nicotine patch and mint snuff (a nonnicotine product) on craving, withdrawal symptoms, and treatment outcome. This study involved a 2 x 2 factorial design, with Active Nicotine Versus Placebo Patch as one of the factors and Mint Snuff Versus No Mint Snuff as the other factor. Spit tobacco users (N = 402, n = 100-101 in each condition) were randomly assigned to 1 of the 4 treatment conditions for a period of 10 weeks. Treatment outcome was measured up to 62 weeks. The results showed that the nicotine patch was effective in increasing short-term abstinence over the placebo patch and in reducing craving and withdrawal signs and symptoms from spit tobacco. Although mint snuff was not effective in enhancing treatment outcome, it reduced craving and withdrawal symptoms. No interaction effects were observed. At this time, the use of the nicotine patch and mint snuff should be primarily considered for the reduction of craving and withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780124

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  15 in total

1.  A randomised clinical trial of nicotine patches for treatment of spit tobacco addiction among adolescents.

Authors:  R C Stotts; P K Roberson; E Y Hanna; S K Jones; C K Smith
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

2.  Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation.

Authors:  Katherine R Schiller; Xianghua Luo; Amanda J Anderson; Joni A Jensen; Sharon S Allen; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2012-01-04       Impact factor: 4.244

Review 3.  Pharmacological interventions for the treatment of smokeless tobacco use.

Authors:  Jon O Ebbert; Karl Fagerstrom
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

4.  Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India.

Authors:  Sonali Jhanjee; Raka Jain; Veena Jain; Tina Gupta; Swati Mittal; Patricia Goelz; Robert A Schnoll
Journal:  J Psychoactive Drugs       Date:  2015-08-28

5.  Factors associated with smokeless tobacco cessation in an Appalachian population.

Authors:  Ross M Kauffman; Amy K Ferketich; Alvin G Wee; Jennifer M Shultz; Patty Kuun; Mary Ellen Wewers
Journal:  Addict Behav       Date:  2008-01-11       Impact factor: 3.913

6.  Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.

Authors:  Jennifer N Gray; Alison B Breland; Michael Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2008-09       Impact factor: 4.244

Review 7.  Tobacco cessation in primary care: maximizing intervention strategies.

Authors:  John D Anczak; Robert A Nogler
Journal:  Clin Med Res       Date:  2003-07

8.  A randomized clinical trial of nicotine lozenge for smokeless tobacco use.

Authors:  Jon O Ebbert; Herbert H Severson; Ivana T Croghan; Brian G Danaher; Darrell R Schroeder
Journal:  Nicotine Tob Res       Date:  2009-10-30       Impact factor: 4.244

9.  A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users.

Authors:  Jon O Ebbert; Ivana T Croghan; Darrell R Schroeder; Richard D Hurt
Journal:  Nicotine Tob Res       Date:  2013-07-19       Impact factor: 4.244

10.  Predictors of smokeless tobacco abstinence.

Authors:  Jon O Ebbert; Elbert D Glover; Eri Shinozaki; Darrell R Schroeder; Lowell C Dale
Journal:  Am J Health Behav       Date:  2008 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.